{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:11:10Z","timestamp":1791227470005,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T00:00:00Z","timestamp":1603929600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA55349"],"award-info":[{"award-number":["CA55349"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA23766"],"award-info":[{"award-number":["CA23766"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1007\/s00262-020-02764-9","type":"journal-article","created":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T15:03:26Z","timestamp":1603983806000},"page":"1189-1202","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer"],"prefix":"10.1007","volume":"70","author":[{"given":"Tao","family":"Dao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin G.","family":"Klatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Korontsvit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Soo","family":"Mun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Guzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Zivanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrisann K.","family":"Kyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas D.","family":"Socci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8217-4554","authenticated-orcid":false,"given":"Roisin E.","family":"O\u2019Cearbhaill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Scheinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,29]]},"reference":[{"key":"2764_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","volume":"348","author":"T Schumacher","year":"2015","unstructured":"Schumacher T, Schreiber RD (2015) Neoantigens in cancer immunotherapy. Science 348:69\u201374. https:\/\/doi.org\/10.1126\/science.aaa4971","journal-title":"Science"},{"key":"2764_CR2","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/nature24473","volume":"551","author":"M Luksza","year":"2017","unstructured":"Luksza M, Riaz N, Makarov V, Balanchandran V, Hellmann MD, Solovyov A et al (2017) A neoantigens fitness model predicts tumor response to checkpoint blockade immunotherapy. Nature 551:517\u2013520. https:\/\/doi.org\/10.1038\/nature24473","journal-title":"Nature"},{"key":"2764_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/ni.3682","volume":"18","author":"E Tran","year":"2017","unstructured":"Tran E, Robbins PF, Rosenberg SA (2017) \u201cFinal common pathway\u201d of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol 18:255\u2013262. https:\/\/doi.org\/10.1038\/ni.3682","journal-title":"Nat Immunol"},{"key":"2764_CR4","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1126\/science.aad1253","volume":"350","author":"E Tran","year":"2015","unstructured":"Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcitte S et al (2015) Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 350:1387\u20131390. https:\/\/doi.org\/10.1126\/science.aad1253","journal-title":"Science"},{"key":"2764_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1126\/science.aaa3828","volume":"348","author":"BM Carreno","year":"2015","unstructured":"Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA et al (2015) Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma noeantigen-specific T cells. Science 348:803\u2013808. https:\/\/doi.org\/10.1126\/science.aaa3828","journal-title":"Science"},{"key":"2764_CR6","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3389\/fimmu.2017.01702","volume":"8","author":"E Braunlein","year":"2017","unstructured":"Braunlein E, Krackhardt AM (2017) Identification and characterization of neoantigens as well as respective immune responses in cancer patients. Front Immunol 8:1702. https:\/\/doi.org\/10.3389\/fimmu.2017.01702","journal-title":"Front Immunol"},{"key":"2764_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3322\/canjclin.51.1.15","volume":"51","author":"RT Greenlee","year":"2001","unstructured":"Greenlee RT, Hill-Harmon MB, Murray T, Thun M (2001) Cancer statistics. CA Cancer J Clin 51:15\u201336. https:\/\/doi.org\/10.3322\/canjclin.51.1.15","journal-title":"CA Cancer J Clin"},{"key":"2764_CR8","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJM199004123221501","volume":"322","author":"RC Young","year":"1990","unstructured":"Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG et al (1990) Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials. N Engl J Med 322:1021\u20131027. https:\/\/doi.org\/10.1056\/NEJM199004123221501","journal-title":"N Engl J Med"},{"key":"2764_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.ygyno.2009.10.074","volume":"116","author":"JK Chan","year":"2010","unstructured":"Chan JK, Tian C, Teoh D, Monk BJ, Herzog T, Kapp DS et al (2010) Survival after recurrence in early-stage high-risk epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 116:307\u2013311. https:\/\/doi.org\/10.1016\/j.ygyno.2009.10.074","journal-title":"Gynecol Oncol"},{"key":"2764_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1038\/nature14410","volume":"521","author":"AM Patch","year":"2015","unstructured":"Patch AM, Christie EL, Etemadmoghadam D, Garsed DW, George J, Fereday S et al (2015) Whole-genome characterization of chemoresistant ovarian cancer. Nature 521:489\u2013494. https:\/\/doi.org\/10.1038\/nature14410","journal-title":"Nature"},{"key":"2764_CR11","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/nature10166","volume":"474","author":"Cancer Genome Atlas Research Network","year":"2011","unstructured":"Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474:609\u2013615. https:\/\/doi.org\/10.1038\/nature10166","journal-title":"Nature"},{"key":"2764_CR12","doi-asserted-by":"publisher","first-page":"18538","DOI":"10.1073\/pnas.0509182102","volume":"102","author":"E Sato","year":"2005","unstructured":"Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F et al (2005) Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+\/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 102:18538\u201318543. https:\/\/doi.org\/10.1073\/pnas.0509182102","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2764_CR13","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"EL Goode","year":"2017","unstructured":"Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W et al (2017) Dose\u2013response association of CD8+ tumor-infiltrating lymphocytes and survival time in high-grade serous ovarian cancer. JAMA Oncol 3:e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290","journal-title":"JAMA Oncol"},{"key":"2764_CR14","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al (2013) Signatures of mutational processes in human cancer. Nature 500:415\u2013421. https:\/\/doi.org\/10.1038\/nature12477","journal-title":"Nature"},{"issue":"24","key":"2764_CR15","doi-asserted-by":"publisher","first-page":"5562","DOI":"10.1158\/1078-0432.CCR-18-0573","volume":"5","author":"DC Deniger","year":"2018","unstructured":"Deniger DC, Pasetto A, Robbins PF, Gartner JJ, Prickett TD et al (2018) T-cell responses to TP53 \u201chotspot\u201d mutations and unique antigens expressed by human ovarian cancers. Clin Cancer Res 5(24):5562\u20135573. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0573","journal-title":"Clin Cancer Res"},{"key":"2764_CR16","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/s41467-018-03301-0","volume":"9","author":"S Bobisse","year":"2018","unstructured":"Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ et al (2018) Sensitive and frequent identification of high avidity neo-epitope specific CD8+ T cells in immunotherapy-na\u00efve ovarian cancer. Nat Commun 9:1092. https:\/\/doi.org\/10.1038\/s41467-018-03301-0","journal-title":"Nat Commun"},{"key":"2764_CR17","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1158\/1078-0432.CCR-18-1731","volume":"24","author":"IA McNeish","year":"2018","unstructured":"McNeish IA (2018) Neoantigen in ovarian cancer: embarrassment of riches or needles in a haystack? Clin Cancer Res 24:5493\u20135495. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1731","journal-title":"Clin Cancer Res"},{"key":"2764_CR18","doi-asserted-by":"publisher","first-page":"a028829","DOI":"10.1101\/cshperspect.a028829","volume":"10","author":"OJ Finn","year":"2018","unstructured":"Finn OJ, Rammensee HG (2018) Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these be overcome? Nothing new in spite of the name. Cold Spring Harb Perspect Biol 10:a028829. https:\/\/doi.org\/10.1101\/cshperspect.a028829","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2764_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4313","author":"B Bulik-Sullivan","year":"2018","unstructured":"Bulik-Sullivan B, Busby J, Palmer CD, Davis MJ, Murphy T, Clark A et al (2018) Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification. Nat Biotech. https:\/\/doi.org\/10.1038\/nbt.4313","journal-title":"Nat Biotech"},{"key":"2764_CR20","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nature14001","volume":"515","author":"M Yadav","year":"2014","unstructured":"Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S et al (2014) Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing. Nature 515:572\u2013576. https:\/\/doi.org\/10.1038\/nature14001","journal-title":"Nature"},{"key":"2764_CR21","doi-asserted-by":"publisher","first-page":"Unit13.20","DOI":"10.1002\/0471250953.bi1320s40","volume":"Chapter 13","author":"M Bern","year":"2012","unstructured":"Bern M, Kil YJ, Becker C (2012) Byonic: advanced peptide and protein identification software. Curr Protoc Bioinform Chapter 13:Unit13.20. https:\/\/doi.org\/10.1002\/0471250953.bi1320s40","journal-title":"Curr Protoc Bioinform"},{"key":"2764_CR22","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz V, Paul S, Andreatta M, Marcatili P, Peters B, Nielsen M (2017) NetMHCpan-4.0: improved peptide-MHC Class I interaction predictions integrating eluted ligand and peptide binding affinity data. J Immunol 199:3360\u20133368. https:\/\/doi.org\/10.4049\/jimmunol.1700893","journal-title":"J Immunol"},{"key":"2764_CR23","doi-asserted-by":"publisher","first-page":"4547","DOI":"10.1158\/1078-0432.CCR-07-0708","volume":"13","author":"R May","year":"2007","unstructured":"May R, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, Maslak P, Scheinberg DA (2007) CD4+ peptide epitopes from WT1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 13:4547\u20134555. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0708","journal-title":"Clin Cancer Res"},{"key":"2764_CR24","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/0090-8258(92)90046-l","volume":"44","author":"HW Hirte","year":"1992","unstructured":"Hirte HW, Clark DA, Mazurka J, O\u2019Connell G, Rusthoven J (1992) A rapid and simple method for the purification of tumor cells from ascetic fluid of ovarian carcinoma. Gynecol Oncol 44:223\u2013226. https:\/\/doi.org\/10.1016\/0090-8258(92)90046-l","journal-title":"Gynecol Oncol"},{"key":"2764_CR25","doi-asserted-by":"publisher","first-page":"e1065369","DOI":"10.1080\/2162402X.2015.1065369","volume":"5","author":"JK Peper","year":"2015","unstructured":"Peper JK, Bosmuller HC, Schuster H, Guckel B, Horzer H, Roehle K et al (2015) HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy. Oncoimmunology 5:e1065369. https:\/\/doi.org\/10.1080\/2162402X.2015.1065369","journal-title":"Oncoimmunology"},{"key":"2764_CR26","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.cell.2017.07.025","volume":"170","author":"A Jimenez-Sanchez","year":"2017","unstructured":"Jimenez-Sanchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y et al (2017) Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell 170:927\u2013938. https:\/\/doi.org\/10.1016\/j.cell.2017.07.025","journal-title":"Cell"},{"key":"2764_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12885-015-1077-4","volume":"15","author":"JY Lee","year":"2015","unstructured":"Lee JY, Yoon JK, Kim B, Kim S, Kim MA, Lim H et al (2015) Tumor evolution and intratumor heterogeneity of an epithelial ovarian cancer investigated using next generation sequencing. BMC Cancer 15:85. https:\/\/doi.org\/10.1186\/s12885-015-1077-4","journal-title":"BMC Cancer"},{"key":"2764_CR28","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.3389\/fimmu.2017.01848","volume":"8","author":"TC Wirth","year":"2017","unstructured":"Wirth TC, Kuhnel F (2017) Neoantigen targeting\u2014dawn of a new era in cancer immunotherapy? Front Immunol 8:1848. https:\/\/doi.org\/10.3389\/fimmu.2017.01848","journal-title":"Front Immunol"},{"issue":"6280","key":"2764_CR29","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351(6280):1463\u20131469. https:\/\/doi.org\/10.1126\/science.aaf1490","journal-title":"Science"},{"key":"2764_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1148\/radiol.11110175","volume":"263","author":"E Sala","year":"2012","unstructured":"Sala E, Kataoka MY, Priest AN, Gill AB, McLean MA et al (2012) Advanced ovarian cancer: multiparametric MR imaging demonstrates response- and metastasis-specific effects. Radiology 263:149\u2013159. https:\/\/doi.org\/10.1148\/radiol.11110175","journal-title":"Radiology"},{"key":"2764_CR31","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.1158\/0008-5472.CAN-15-1082","volume":"75","author":"SF Ngiow","year":"2015","unstructured":"Ngiow SF, Young A, Jacquelot N, Yamazaki T, Enot D, Zitvogel L, Smyth MJ (2015) A threshold level of intratumor CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res 75:3800\u20133811. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1082","journal-title":"Cancer Res"},{"key":"2764_CR32","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.cell.2016.08.069","volume":"167","author":"J Gao","year":"2016","unstructured":"Gao J, Shi LZ, Zhao H, Chen J, Xiong L, He Q et al (2016) Loss of IFN-\u03b3 pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167:397\u2013404. https:\/\/doi.org\/10.1016\/j.cell.2016.08.069","journal-title":"Cell"},{"key":"2764_CR33","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN (2018) T cell dysfunction in cancer. Cancer Cell 33:547\u2013562. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.012","journal-title":"Cancer Cell"},{"key":"2764_CR34","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1158\/1078-0432.CCR-13-2147","volume":"20","author":"DA Wick","year":"2013","unstructured":"Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR et al (2013) Surveillance of the tumor mutatome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res 20:1125\u20131134. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2147","journal-title":"Clin Cancer Res"},{"key":"2764_CR35","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1126\/science.aaf2288","volume":"352","author":"E Stronen","year":"2016","unstructured":"Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W et al (2016) Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. Science 352:1337\u20131341. https:\/\/doi.org\/10.1126\/science.aaf2288","journal-title":"Science"},{"key":"2764_CR36","doi-asserted-by":"publisher","first-page":"1599640","DOI":"10.1080\/2162402X.2019.1599640","volume":"8","author":"MO Holmstrom","year":"2019","unstructured":"Holmstrom MO, Hasselbalch HC, Andersen MH (2019) Neo-antigen specific memory T-cell responses in healthy individuals. Oncoimmunology 8:1599640. https:\/\/doi.org\/10.1080\/2162402X.2019.1599640","journal-title":"Oncoimmunology"},{"key":"2764_CR37","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3389\/fimmu.2017.0171830","volume":"8","author":"T Karpanen","year":"2017","unstructured":"Karpanen T, Olweus J (2017) The potential of donor T-cell repertories in neoantigen-targeted cancer immunotherapy. Front Immunol 8:1718. https:\/\/doi.org\/10.3389\/fimmu.2017.0171830","journal-title":"Front Immunol"},{"key":"2764_CR38","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1158\/1078-0432.CCR-05-1672","volume":"12","author":"B Kubuschok","year":"2006","unstructured":"Kubuschok B, Neumann F, Seater M, Schormann C, Wagner C et al (2006) Naturally occurring T-cell response against mutated p21 Ras oncoprotein in pancreatic cancer. Clin Cancer Res 12:1365\u20131372. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-1672","journal-title":"Clin Cancer Res"},{"key":"2764_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1097\/COC.0b013e3181e84b1f","volume":"34","author":"GK Abou-Alfa","year":"2011","unstructured":"Abou-Alfa GK, Chapman PB, Feilchenfeldt J, Brennan MF, Capanu M et al (2011) Targeting mutated K-ras in pancreatic adenocarcinoma using an adjuvant vaccine. Am J Clin Oncol 34:321\u2013325. https:\/\/doi.org\/10.1097\/COC.0b013e3181e84b1f","journal-title":"Am J Clin Oncol"},{"key":"2764_CR40","unstructured":"Scheinberg DA, Dao T, Liu C (2017). Monoclonal antigen-binding proteins to intracellular oncogene products. Patent; US20180134804A1."},{"key":"2764_CR41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/path.2696","volume":"221","author":"AA Ahmed","year":"2010","unstructured":"Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG et al (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221:49\u201356. https:\/\/doi.org\/10.1002\/path.2696","journal-title":"J Pathol"},{"key":"2764_CR42","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1158\/2326-6066.CIR-18-0686","volume":"7","author":"W Lo","year":"2019","unstructured":"Lo W, Parkhurst M, Robbins PF, Tran E, Lu YC et al (2019) Immunologic recognition of a shared p53 mutated neoantigen in a patient with metastatic colorectal cancer. Cancer Immunol Res 7:534\u2013543. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0686","journal-title":"Cancer Immunol Res"},{"key":"2764_CR43","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1172\/JCI123791","volume":"129","author":"P Malekzadeh","year":"2019","unstructured":"Malekzadeh P, Pasetto A, Robbins PF, Parkhurst MR, Paria BC et al (2019) Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. J Clin Invest 129:1109\u20131114. https:\/\/doi.org\/10.1172\/JCI123791","journal-title":"J Clin Invest"},{"key":"2764_CR44","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1002\/ijc.22584","volume":"120","author":"D Ito","year":"2007","unstructured":"Ito D, Visus C, Hoffmann T, Balz V, Bier H, Appella E et al (2007) Immunological characterization of missense mutations occurring within cytotoxic T cell-defined p53 epitopes in HLA-A*02:01+ squamous cell carcinomas of the head and neck. Int J Cancer 120:2618\u20132624. https:\/\/doi.org\/10.1002\/ijc.22584","journal-title":"Int J Cancer"},{"key":"2764_CR45","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.2174\/138161212802002805","volume":"18","author":"R Vermeij","year":"2012","unstructured":"Vermeij R, Leffers N, Melief CJ, Daemen T, Nijman HW (2012) Antigen-specific immunotherapy in ovarian cancer and p53 as tumor antigen. Curr Pharm Des 18:3804\u20133811. https:\/\/doi.org\/10.2174\/138161212802002805","journal-title":"Curr Pharm Des"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02764-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-020-02764-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02764-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T01:09:26Z","timestamp":1618621766000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-020-02764-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,29]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["2764"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02764-9","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,29]]},"assertion":[{"value":"24 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"David Scheinberg is on the advisory board of, has received consulting fees from, and\/or has equity in Progenics Pharmaceuticals, Sellas, KLUS, Iovance Biotherapeutics, Inc., Pfizer, Actinium Pharmaceuticals, Inc., OncoPep, and Eureka Therapeutics. Tao Dao has equity in Eureka Therapeutics. Dr O'Cearbhaill's institution receives funding for clinical research that she is leading from Celgene\/Juno, Tesaro\/GSK, Ludwig Cancer Institute, Abbvie, Regeneron, TCR2 Therapeutics, Atara Biotherapeutics, MarkerTherapeutics, Syndax Pharmaceuticals, Genmab Therapeutics, Sellas Therapeutics, Genentech, Kite Pharma, and the Gynecologic Oncology Foundation. Dr O\u2019Cearbhaill has served on a once-off advisory board for Regeneron, Genmab Therapeutics, and GSK. All other authors declare no conflict or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB Human Subject Assurance Number FW00004998) and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}